When a stock rises 40% in a year nobody asks what multiple they are paying. When it falls 36% in a day everybody blames the regulator. Both reactions skip the same question.
What happened
On 24 September PB Fintech, the parent of Policybazaar and Paisabazaar, closed at ₹1,207.20, down 36.0% from ₹1,886.30, its worst day since listing in November 2021. It opened 10% lower and never bounced; 2.7 crore shares changed hands, nineteen times a normal day. About ₹31,000 crore of market value went in one session. Two days earlier the stock had been within 4% of its 52-week high.
The trigger was IRDAI's consultation paper on insurance distribution, released the previous evening. It proposes cutting insurers' expenses of management from 30% of premium to 20% over five years (15% then 12.5% for life insurers), and capping commissions product by product: 2 to 2.5% on loan-linked term cover, 5% on motor own-damage, nothing on motor third-party, with health commissions also reset sharply lower. Comments are open until 25 October; nothing is law yet. Jefferies' rule of thumb is that a 10% cut in new-business commission rates takes 10 to 12% off a distributor's earnings. Emkay was blunter: a cut this size "would make insurance distribution an unviable business."
The rest of the sector sold off in proportion to its dependence on paid distribution: Turtlemint, the other listed distributor, locked at its 20% lower circuit; Max Financial fell 9.8%, HDFC Life 6.2%, ICICI Prudential Life 4.1%. ICICI Lombard rose 5%. Nifty was down 1.6%.
Was the company the problem?
No. FY26 was PB Fintech's best year: revenue ₹6,794 crore, up 37%; profit ₹670 crore, up 115%; insurance premium through the platform ₹29,934 crore, up 42%. Q1 FY27 kept the pace, revenue up 40% and profit up 92% to ₹163 crore. The balance sheet has ₹2,550 crore of cash and almost no debt. In online insurance distribution it has no listed competitor of comparable scale. Whatever the final rules say, the customers who compare and buy insurance online will still go somewhere, and that somewhere is mostly Policybazaar.
A young profit and an old multiple
What the FY26 numbers hide is how new the profit is. PB Fintech lost money in every year from FY15 to FY23, about ₹2,350 crore in total, including ₹833 crore in FY22, the year after it listed. The first profit came in FY24: ₹64 crore, on revenue of ₹3,438 crore. FY25 was the first year operating profit turned positive at all, ₹94 crore. And of FY26's ₹707 crore pre-tax profit, ₹372 crore was other income, mostly interest on the IPO cash; the operating business earned ₹508 crore.
| ₹ crore | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,425 | 2,558 | 3,438 | 4,977 | 6,794 |
| Operating profit | −901 | −662 | −188 | 94 | 508 |
| Other income | 124 | 259 | 381 | 449 | 372 |
| Net profit | −833 | −488 | 64 | 353 | 670 |
So the market was paying 130 times earnings for a company with two full years of profit behind it, whose operating margin had reached 7.5% for the first time, and where more than half of pre-tax profit was treasury income. A multiple like that isn't a judgement on the business as it stands; it is a bet that 30 to 40% growth continues for a decade and that the take rate, the commission earned on every rupee of premium, holds or rises. Nothing about that bet was defensible on the numbers, only on the momentum. A valuation that can't be defended on the numbers doesn't need a regulator to correct it; it needs an excuse, and the paper was the excuse.
Then why 36%?
Because of what the stock was priced at on the 23rd. At ₹1,886 the company was worth ₹87,000 crore: 130 times FY26 profit, 117 times trailing profit, 12 times sales and roughly 92 times EBITDA. The regulator did not touch this year's earnings; it touched the assumption the multiple was built on.
Look at the arithmetic. After the fall the stock trades at about 83 times FY26 profit and 75 times trailing. A 36% drop with earnings unchanged is a multiple compression from 130 to 83, and 83 is still not cheap for a business whose pricing power a regulator has just questioned. Four brokerages still carry targets between ₹1,590 and ₹2,310. All of them were written before the paper.
The pattern
This is not specific to insurance. A stock at 130 times earnings has no cushion; there is no dividend yield, no book value, no cash-flow multiple where a buyer steps in and says "cheap enough." When the growth story takes a hit, the only floor is the next story. Traders will call this regulatory risk, and it is, but regulatory risk was as real at ₹1,886 as at ₹1,207. What changed is that the market was reminded of it on a day when the price had no room to absorb the reminder. The higher you fly on a multiple, the harder you land when something questions the multiple.
Benjamin Graham said it plainly in The Intelligent Investor: "It is absurd to think that the general public can ever make money out of market forecasts." Nobody could have priced how high PB Fintech would climb or how far it would fall in a day. What an investor can decide is much simpler: whether the price is cheap enough to buy or expensive enough to sell. At 130 times a two-year-old profit, that decision had answered itself long before IRDAI wrote a word.
Verdict
The business is intact and dominant, and it will likely recover some of this once the final rules land and are less severe than the draft, as drafts usually are. But the 36% is not the regulator's doing. It is the price of having paid 130 times earnings for certainty that no regulated business can offer.
Educational purposes only, not investment advice. DYOR.
Sources: NSE closing data, 22 to 24 September 2026; IRDAI consultation paper on insurance distribution, 23 September 2026 (comments to 25 October); PB Fintech annual financials FY15 to FY26 and Q1 FY27 results; Jefferies and Emkay notes as reported by Business Today, 24 September 2026; Benjamin Graham, The Intelligent Investor.
Follow along: @tyrovirtuoso on X